Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025 | RDGL Stock News

Author's Avatar
Apr 23, 2025
Article's Main Image
  • IsoPet® animal cancer treatments grew 150% year-over-year in Q1 2025, treating 15 pets.
  • Vivos Inc. expanded to 14 certified clinics, adding three new facilities in Q1.
  • The global veterinary oncology market is valued at $1.18 billion, with a projected 11.3% CAGR through 2030.

Vivos Inc. (OTCQB: RDGL) has reported a notable milestone in its IsoPet® Animal Cancer Division, achieving a 150% year-over-year increase in treatment volume in Q1 2025. The breakthrough was driven by the company's Precision Radionuclide Therapy™, which treated 15 pets, reflecting significant growth from the previous year.

The company's expansion efforts included the activation of three new certified clinics, bringing the total to 14 facilities across the United States. This network consists of eight small animal clinics and six equine clinics, enhancing accessibility for pet owners seeking cutting-edge cancer treatments. New clinics such as Brazos Equine Hospital in Texas and Sumner Veterinary Hospital in Washington were among the recent additions.

IsoPet® made significant advancements in equine oncology, specifically with ocular squamous cell carcinoma treatments. The division treated four horses, employing pioneering techniques like direct cornea injections, providing new hope for conditions with traditionally limited options.

Vivos Inc. also reported a successful biweekly production schedule of yttrium-90 hydrogel, ensuring a consistent supply for ongoing treatment demands. Notable treatments have occurred at facilities such as NorthStar Vets in New Jersey and Brazos Equine Hospital in Texas.

The company's strategic marketing initiatives, including participation in major veterinary conferences and increased social media engagement, have expanded its outreach, leading to a noticeable rise in treatment inquiries.

The global veterinary oncology market, projected to grow at an 11.3% CAGR through 2030, is an arena where IsoPet® is well-positioned, offering a non-invasive, cost-effective alternative to traditional radiation therapies for cancer treatment in pets.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.